

Signaling pathways

Katka Hemalová



March 20, 2014


1 Signaling pathways

2 FGFR pathway


3 Yamada *et al.* model

Signals


(A) Endocrine signaling




(B) Paracrine signaling




(C) Direct cell-to-cell signaling




(D) Autocrine signaling




Cell signaling




Response time



Receptors




Signal transduction through molecular switches



- Other ways to switch a protein on/off: binding of another signaling protein, cAMP, Ca²⁺ or by another modification (e.g. ubiquitylation)

Scaffold proteins


- Signaling proteins in close proximity
- Fast, efficient, selective response to an extracellular signal
- Avoiding unwanted cross-talk




The three largest classes of cell-surface receptor

- Ion-channel-coupled receptors
- G-protein-coupled receptors
- Enzyme-coupled receptors


Ion-channel-coupled receptors




G-protein coupled receptors




cAMP activates Protein kinase A




Enzyme-coupled receptors



Enzyme-coupled receptors




SH2 domain ("SRC-Homology 2 domain")




- crucial part of adaptors (Grb2, Shc, Crk, ...)

Grb2 and Ras pathway




- Grb2-SOS complex preexist in cytoplasm

Ras pathway (MAPK pathway)



Fibroblast growth factor receptor 3 (FGFR3)


- Enzyme-coupled receptor
- Growth and proliferation inhibition
- Mutation that cause achondroplasia act by exaggerating the negative regulatory functions of FGFR3




FGFR3-related skeletal dysplasia

Hypochondroplasia
Achondroplasia
SADDAN
Thanatophoric Dysplasia

STATURE







- FGFRs employ several signaling pathways, MAPK pathway is one of them

1, FGFR3 tyrosine kinase; 2, ligand-mediated receptor activation; 3, CNP-mediated antagonism of signals downstream of receptor; 4, expression or synthesis of mutant FGFR3; 5, tyrosine kinase mediators of MAPK signaling pathway; 6, degradation of activated receptor. See text for discussion.

Constitutive activation of ERK




- Mutated FGFR3 induces constitutive activation of the MAPK pathway in chondrocytes
- Disease results from increased signal from the mutant receptor



- FGFRs recruit their downstream adaptors (GAB1, SHC, FRS2, etc.)



EGF vs. FGF pathway model schema (Yamada *et al.*, 2004)



- Grb2-SOS binds EGFR directly or through Shc
- Grb2-SOS binds FGFR through FRS2

EGF vs. FGF pathway (Yamada *et al.*, 2004)

- Duration of ERK activation determines the cell response
- EGF induces transient ERK activation
- FGF induces transient and sustained ERK activation
- What is the reason for difference in time course?



Dependency on Shc and FRS2 initial concentration

- Grb2-SOS binds EGFR directly or through Shc → ERK activation is limited by concentration of receptor
 - $[EGFR2P] + [Grb2-SOS] \leftrightarrow [EGFR2P-Grb2-SOS]$
 - $[EGFR2P-ShcP] + [Grb2-SOS] \leftrightarrow [EGFR2P-ShcP-Grb2-SOS]$
- Grb2-SOS binds FGFR through FRS2 → signal amplification
 - $[FGFR2P] + [FRS] \leftrightarrow [FGFR2P-FRS]$
 - $[FGFR2P-FRS] \rightarrow [FGFR2P] + [FRSP]$
 - $[FRSP] + [Grb2-SOS] \leftrightarrow [FRSP-Grb2-SOS]$

EGF vs. FGF pathway summary

- Differences in mechanism of interaction between receptors and first adapters
- FRS2 and sustained ERK activation (more Grb2-SOS complexes are recruited)